Zhongtong Finance APP learned that CMS (00867) rose by more than 5% in the afternoon, and as of press time, it rose by 4.78%, reporting HKD 6.79, with a turnover of HKD 43.6359 million.

Guoyuan International pointed out that the company's three innovative drugs, namely, dexmedetomidine nasal spray, toripalimab injection, and methotrexate injection-silver psoriasis, have all been included in the national medical insurance catalog. The fourth innovative drug, saccharose hydroxyoxide iron chewable tablets (Vefuray), obtained authorization in February 2024, and it is the first iron-based non-calcium phosphate binder in China used to control the serum phosphate level in patients with chronic kidney disease undergoing hemodialysis. These four new drugs are conservatively estimated to contribute 400-500 million yuan in revenue in 2024. The fifth innovative drug, methylene blue enteric-coated slow-release tablets, was approved for listing in June this year. The company has launched five innovative drugs in the past year, fully demonstrating the efficiency of its research and development. These innovative drugs are expected to drive rapid growth in performance.

The bank pointed out that the company has laid out 30 innovative pipelines mainly based on FIC and BIC globally, and methotrexate injection for RA has been accepted; more than 10 registration clinical trials are also underway in an orderly manner. In addition, the CMS Beauty product line is constantly enriching. It will introduce Lenvima cream in 2022. The products also include skincare products and hyaluronic acid and botulinum products. The ophthalmology team has more than 350 people, strengthening the layout of medical devices and commercial capabilities, and driving rapid growth in performance.